Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general populationCOVID-19 백신 접종 및/또는 일반 인구의 감염 후 이종 SARS-CoV-2 체액 반응Article Published on 2022-05-212022-09-12 Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Adults age Anti-spike anti-Spike IgG assessment characterized correlated COVID-19 COVID-19 vaccination Critical decrease defined determinant Follow-up French Gender General population heterogeneity highlight humoral Infection intensity participant positively correlated profile protocol Reinfection SARS-CoV-2 SARS-COV-2 infection serological survey Serological testing subjects the antibody response the vaccine uninfected vaccination vaccine injection [DOI] 10.1038/s41598-022-11787-4 PMC 바로가기 [Article Type] Article
Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy생물학적 치료에 대한 중증 천식 환자에서 mRNA 백신 유도 SARS-CoV-2-특이적 체액 및 세포 면역의 효과 및 지속성Article Published on 2022-05-202022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome age Asthma asthma patient Biological BNT162b2 mRNA vaccine cellular cellular immunity coronavirus Coronavirus disease 2019 COVID-19 COVID-19 vaccination declined decrease dose doses Effectiveness Efficacy elicit elicited evaluated healthy humoral Humoral immunity Immunity impacted mRNA not affect Patient populations regimen SARS-CoV-2 second dose severe asthma patients on biological therapy. significantly the vaccine therapy treated Treatment vaccination Vaccine Vaccine-induced immunity [DOI] 10.3389/fimmu.2022.892277 PMC 바로가기 [Article Type] Article
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 VaccineBNT162b2 코비드-19 백신 3차 접종의 안전성 및 효능Clinical Trial Published on 2022-05-192022-09-25 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 임상, 진단, 치료법, [키워드] 95% confidence interval active immunization acute respiratory syndrome Administered age assigned BNT162b2 BNT162b2 vaccine booster coronavirus coronavirus disease Critical dose Efficacy evaluated event Evidence Follow-up Infection injected median median interval myocarditis of BNT162b2 Older pandemic participant Pfizer-BioNTech phase 3 trial Placebo placebo-controlled provided Randomized reported Safety SARS-CoV-2 SARS-COV-2 infection second dose systemic reactogenicity the median the placebo group the vaccine Vaccine [DOI] 10.1056/NEJMoa2200674 PMC 바로가기 [Article Type] Clinical Trial
mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functionsmRNA-1273 및 BNT162b2 COVID-19 백신은 Fc 매개 효과기 기능에 차이가 있는 항체를 유도합니다Article Published on 2022-05-182022-09-11 Journal: Science Translational Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody approved binding BNT162b2 cell activation Cohort Concentration coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Efficacy elicit epitope evade Fc-mediated effector function function functional functional capacity Hospital staff humoral immune response humoral immune responses IgA immune response immune responses Killer cell morbidity morbidity and mortality mRNA mRNA vaccines mRNA-1273 mRNA-1273 vaccine mRNA-1273 vaccines N-terminal N-terminal domain natural killer natural killer cell neutralization Neutralizing antibodies neutrophil phagocytosis potential differences protective immunity RBD Receptor binding domain recipient recipients reduced Region respiratory responses robust SARS-CoV-2 the vaccine the vaccines These data Vaccine Vaccines variants variants of concern Variation Viral viral variant Viral variants wake wild-type [DOI] 10.1126/scitranslmed.abm2311 PMC 바로가기 [Article Type] Article
An assessment of the vaccination of school-aged children in England against SARS-CoV-2SARS-CoV-2에 대한 영국의 취학 연령 아동 예방 접종 평가Article Published on 2022-05-182022-09-11 Journal: BMC Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] adverse event adverse events age Analysis assumed average benefit childhood children Cohort COVID-19 death deaths delta variant Efficacy England Evidence expansion facilitate generate greater group Health hospital Hospital admission Hospital admissions immunisation individual Infection interactions involved knowledge less lower risk mathematical mathematical model Measures projection public health reduced reduction reduction in Relaxation reported resource SARS-CoV-2 Spread substantial reduction substantial reductions suggested the vaccine vaccination Vaccine vaccine administration vaccine efficacy with infection [DOI] 10.1186/s12916-022-02379-0 PMC 바로가기 [Article Type] Article
The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs브라질의 COVID-19 퇴치를 위한 지원 격차: 예방 접종이 누구를 위해, 어디서, 언제 발생합니까?Article Published on 2022-05-172022-09-11 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 치료기술, [키워드] adopted age analysed Analysis AstraZeneca Brazil calculated carried Cluster Clusters combating Complete CoronaVac country Coverage COVID-19 COVID-19 pandemic COVID-19 pandemics deaths detect dose epidemiological Evolution expected Final first dose followed by group groups healthcare worker Healthcare workers highest highlight identify immunisation Immunisation programs indicated Kernel lowest number of infected occur P-value pandemic performed Point Poisson Population Prevent Probability Region regions second dose Social vulnerability Spatial analysis Temporal Temporal analysis the vaccine vaccination vaccination coverage vaccination rate vaccination rates vaccination schedule Vaccine was performed [DOI] 10.1186/s12879-022-07449-5 PMC 바로가기 [Article Type] Article
Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial성인을 위한 SARS-CoV-2 비활성화 백신의 3회 용량 요법의 면역원성 및 안전성: 무작위, 이중 맹검, 위약 대조 2상 시험Clinical Trial Published on 2022-05-162022-09-12 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 3-dose regimen acute respiratory syndrome Adults Adverse AEs antibody Antibody Response Control coronavirus dose doses double-blind Effective vaccines elicited event geometric mean titer GMT GMTs immune response immunogenicity Immunoglobulin inactivated Inactivated vaccine Injection-site pain intensity Neutralizing Neutralizing antibodies Older pandemic percentage Phase 2 Placebo placebo-controlled trial predominant pseudovirus Randomized receive Receptor binding domain robust Safety safety profile SARS-CoV-2 SARS-CoV-2 inactivated vaccine second dose separated serious AE tested the vaccine vaccination Vaccine virus were recorded [DOI] 10.1093/infdis/jiab627 PMC 바로가기 [Article Type] Clinical Trial
An excitation wavelength-optimized, stable SERS biosensing nanoplatform for analyzing adenoviral and AstraZeneca COVID-19 vaccination efficacy status using tear samples of vaccinated individuals백신 접종자의 눈물 샘플을 사용하여 아데노바이러스 및 AstraZeneca COVID-19 예방 접종 효능 상태를 분석하기 위한 여기 파장 최적화된 안정적인 SERS 바이오 센싱 나노 플랫폼Article Published on 2022-05-152022-09-11 Journal: Biosensors & bioelectronics [Category] COVID19(2023년), SARS, 치료기술, [키워드] Adenovirus antibody AstraZeneca AZD1222 ChAdOx1 COVID-19 vaccination Efficacy Epidemic Epidemic keratoconjunctivitis fluids Hypothesis identify Immunoglobulin Immunoglobulin G Keratoconjunctivitis lAbel Label-free SERS biosensing platform limit of detection marker Near- and far-field properties Non-invasive Oxford-AstraZeneca Oxford-AstraZeneca vaccine Patient platform product receive reproducibility robust robustness scattering stability Stability and robustness Standard deviation Tear Tear fluids. tears the vaccine vaccinated individual vaccinated individuals vaccination Vaccination Status Vaccine [DOI] 10.1016/j.bios.2022.114079 PMC 바로가기 [Article Type] Article
Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine혈청전환 패널은 mRNA-1273 백신 투여 후 항-SARS-CoV-2 항체 개발을 보여줍니다Article Published on 2022-05-112022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] administration analyzed anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibody Antibody Response anticipated collected COVID-19 disease facilitate first vaccination healthcare worker IgG Immunity immunoglobulins Immunological response individual injection Moderna mRNA-1273 vaccine older subjects overcome pandemic Panel positive positive response pre-vaccination SARS-CoV-2 second dose Seroconversion Seroconversion panel Serological assay significantly subject tested the vaccine vaccination Vaccine viral disease [DOI] 10.1016/j.vaccine.2022.04.006 PMC 바로가기 [Article Type] Article
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age6~11세 어린이의 mRNA-1273 Covid-19 백신 평가Clinical Trial Published on 2022-05-112022-09-25 Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료법, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered Adults age Analysis assigned authority B.1.617.2 children circulating coronavirus coronavirus disease criterion development dominant dose effective Efficacy Estimated events fatigue groups headache immune response incidence Infection Inflammatory injection Injection-site pain Interim interquartile range median mRNA-1273 mRNA-1273 vaccine myocarditis Neutralizing antibody titer observer-blinded open label Part participant phase 2–3 trial phase 3 trial Placebo placebo-controlled Prevent public health Randomly receive reported response Result Safe Secondary objective selected Serious Adverse Events Serologic response Symptoms syndrome the vaccine transient adverse Trial Vaccine variant was selected Year [DOI] 10.1056/NEJMoa2203315 PMC 바로가기 [Article Type] Clinical Trial